SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001209191-20-047287
Filing Date
2020-08-18
Accepted
2020-08-18 18:18:58
Documents
1
Period of Report
2020-08-11

Document Format Files

Seq Description Document Type Size
1 FORM 4/A SUBMISSION doc4a.html 4/A  
1 FORM 4/A SUBMISSION doc4a.xml 4/A 3627
  Complete submission text file 0001209191-20-047287.txt   5030
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE109 PRINCETON NJ 08540
Business Address
Lochner Daniel (Reporting) CIK: 0001791187 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-39112 | Film No.: 201114828